Metformin

What metformin is, and who takes it

Metformin is a prescription tablet that lowers blood sugar in adults with type 2 diabetes. It works mainly by telling the liver to release less glucose and by helping muscle respond better to insulin. Clinicians usually reach for it first, alongside changes to food and activity. It is not insulin, and it is not approved for weight loss.

The drug belongs to a class called biguanides. A detailed pharmacology summary from the NIH bookshelf notes that the FDA approved it for type 2 diabetes in 1994, and it has been one of the most prescribed medicines in the United States since. Almost every version dispensed today is a generic, which matters a great deal once you get to what a month actually costs.

It is typically prescribed for adults whose blood sugar stays high despite diet and exercise. Some immediate-release products are also approved for children aged 10 and older, but pediatric approval differs by product, so the specific label on your bottle is what counts. It is not recommended for people with type 1 diabetes, because it does not replace the insulin their bodies no longer make.

You will also find this ingredient inside fixed-dose combination tablets that pair it with a second class of diabetes drug. Sitagliptin plus metformin hydrochloride, sold under brands including Janumet and Zituvimet, is one example. Sitagliptin is a DPP-4 inhibitor, a different mechanism that nudges the body to release insulin after meals. Combination tablets carry the biguanide warnings plus the warnings of the partner ingredient, so read both. Other diabetes and metabolic drugs are covered in the Medication Guides Index.

How it lowers blood sugar

Three effects do most of the work. The liver makes less new glucose overnight and between meals. Muscle and fat tissue become somewhat more sensitive to the insulin you already produce. And a little less glucose is absorbed from the gut. Researchers still debate the exact molecular chain of events; work summarised by university scientists studying how the drug acts on the liver points to energy-sensing pathways inside cells rather than a single switch.

One practical consequence follows from that mechanism. Because the drug does not force the pancreas to pump out insulin, it rarely causes low blood sugar when taken on its own. That changes if it is combined with insulin or a sulfonylurea, where hypoglycemia becomes a real risk to plan for.

The effect is not instant. Blood sugar readings usually shift over days to weeks, and the number clinicians track is A1c, a blood test that reflects your average glucose over roughly three months. Home glucose readings tell you about today; A1c tells you about the trend. If you want to translate between the two measures, the site keeps a set of Free Health Calculators for that kind of conversion.

It is also worth knowing what this medicine does not do. It does not cure type 2 diabetes, and stopping it usually means blood sugar drifts back up. It is a management tool that works best beside sleep, movement, and eating patterns you can sustain.

What the label approves it for

The approved use is narrow and specific: as an addition to diet and exercise, to improve blood sugar control in adults with type 2 diabetes. That is the whole indication. Everything else you may have read about is either a limitation or an off-label use.

The labeling also spells out limits. It is not recommended in type 1 diabetes. For the sitagliptin combination products, the label notes they have not been studied in people with a history of pancreatitis, which is a signal to raise that history with a prescriber rather than a reason to panic.

Off-label prescribing is where most search traffic actually lands: polycystic ovary syndrome, prediabetes, and weight gain linked to some psychiatric medicines. Off-label use is legal and common in US medicine, and it can be evidence-based. It simply means the FDA has not reviewed and approved that particular use for that product, so the strength of the evidence varies by condition. The federal public health picture of diabetes prevalence and complications explains why the glucose indication gets so much clinical attention.

Side effects most people notice first

Digestive upset is by far the most common complaint. Diarrhea, nausea, vomiting, gas, stomach cramping, reduced appetite and a metallic taste all appear in patient-facing summaries such as the National Library of Medicine drug information page for this medicine. For many people these effects fade over the first few weeks. For some they do not, and that is a legitimate reason to go back to the prescriber rather than quietly quit.

Two standard clinical strategies exist for gut symptoms: taking doses with food, and switching to an extended-release version. Both are prescriber decisions, not adjustments to make on your own, because changing form can change how the dose behaves.

Long-term use can lower vitamin B12 levels. Labeling advises periodic checks of blood counts and B12 in people on the drug for years. Low B12 can show up as unusual tiredness, pale skin, or numbness and tingling in the hands and feet, and it is treatable once found. That is a strong argument for keeping up with routine bloodwork.

Searches split by sex are common, and the honest answer is that the labeling does not describe different adverse reaction profiles for women and men. Questions about female-specific effects usually trace back to off-label use in polycystic ovary syndrome, where returning ovulation and cycle changes can occur. Questions from men usually trace to B12 and to general fatigue. Neither pattern changes the core side effect list.

Serious risks, warnings and kidney function

This medicine carries a boxed warning, the FDA’s most serious label warning, for lactic acidosis. It is rare, but it can be fatal. Lactic acid builds up when the drug accumulates in the body, usually because something else has gone wrong at the same time.

The reported signs are non-specific and easy to dismiss: feeling generally unwell, muscle aches, trouble breathing, unusual sleepiness, stomach pain, feeling cold, low blood pressure, and a slow or irregular heartbeat. Treat that cluster as an emergency, not as a bad day.

Risk factors named in the labeling include reduced kidney function, certain other medicines, age 65 and older, iodinated contrast used in imaging scans, surgery, dehydration, heavy alcohol use, liver problems, and conditions that lower oxygen delivery such as decompensated heart failure or serious infection.

The drug is contraindicated in severe kidney impairment, in known hypersensitivity to it, and in acute or chronic metabolic acidosis including diabetic ketoacidosis. Kidney function is the gate that matters most. In 2016 the agency revised the kidney warnings to use estimated glomerular filtration rate rather than creatinine alone, which allowed some people with mild to moderate impairment to use it safely under monitoring.

Your lab report lists a creatinine value; eGFR is the derived number clinicians actually use to decide whether this drug is on the table and how closely to watch you.

Two situations call for a temporary pause, arranged in advance with the prescriber: certain imaging studies that use iodinated contrast dye, and surgery or procedures involving restricted food and fluids. Sudden illness with vomiting, diarrhea or fever also deserves a call, because dehydration is a risk multiplier.

When to get urgent help

Seek emergency care for the lactic acidosis signs above. Get urgent care for severe, persistent stomach pain that may spread to the back, with or without vomiting, which can indicate pancreatitis and is specifically flagged for the sitagliptin combination products. Treat severe low blood sugar with confusion or loss of consciousness as an emergency, especially if you also take insulin or a sulfonylurea. Swelling of the face or throat, trouble breathing, or a spreading rash needs immediate attention.

Interactions and what to disclose

Interactions here fall into a few clear groups, and the practical takeaway is to hand over a complete medicine list including over-the-counter products and supplements. A clinical reference such as the Mayo Clinic oral route drug monograph for this medication lists them in detail.

• Drugs that slow clearance by the kidney, which can raise blood levels of the biguanide. Examples named in labeling include cimetidine, ranolazine, vandetanib and dolutegravir.
• Carbonic anhydrase inhibitors such as topiramate, acetazolamide and zonisamide, which can increase acid in the blood and therefore lactic acidosis risk.
• Alcohol, which affects how the liver handles lactate. Heavy or binge drinking is a specific warning, not a general caution.
• Iodinated contrast agents used in some CT scans and other imaging.
• Medicines that push blood sugar up, including corticosteroids, some diuretics, some antipsychotics and thyroid replacement, which can blunt glucose control.
• Medicines that push blood sugar down, especially insulin and sulfonylureas, where dose planning is needed to avoid hypoglycemia.

Beyond the medicine list, tell a prescriber about kidney or liver disease, heart failure, past pancreatitis, heavy alcohol use, planned surgery or imaging, and any pregnancy or breastfeeding plans. Pregnancy management in type 2 diabetes changes quickly and is handled case by case, so that conversation belongs with an obstetric and diabetes team rather than a search engine.

Immediate release, extended release and brand versions

Two oral forms dominate. Immediate-release tablets release the drug quickly and are usually taken with meals more than once a day. Extended-release tablets release it slowly over hours and are usually taken once daily. There is also an oral solution for people who cannot swallow tablets.

Brand names you may see include Glucophage and Glucophage XR, plus extended-release products Fortamet, Glumetza and the Riomet oral solution. Generic tablets must meet FDA bioequivalence standards, so a generic is expected to perform like the brand it copies. The caveat sits with extended-release products: different brands use different delivery technologies, and they are not automatically interchangeable with each other, so a pharmacy substitution question is worth asking.

Manufacturing history is also fair to know. In 2020 the agency asked some companies to recall specific extended-release lots over an impurity called NDMA, and it published running updates on the affected products and testing results. Those recalls were product-specific rather than class-wide, and the drug remained in wide use.

Weight, PCOS and comparisons with GLP-1 medicines

Weight is the most searched question and the one with the softest answer. This drug is not approved for weight management. It is often described as weight-neutral or associated with small losses, and appetite reduction from digestive side effects can play a part. The long-running federal prevention research, summarised by the NIH institute that ran the Diabetes Prevention Program” , found modest weight change and fewer people progressing to type 2 diabetes than with placebo. Modest is the operative word.

Polycystic ovary syndrome is a second common off-label use, aimed at the insulin resistance that often accompanies it. Federal patient information on how polycystic ovary syndrome is evaluated and managed describes insulin-sensitising treatment as one option among several, with results that vary between individuals.

The comparison with GLP-1 medicines comes up constantly, so here is the plain structure of the difference.

They are not the same drug, and they are not interchangeable. Some people take both, because they act by different routes. If you are weighing the injectable options, the mechanism and safety detail sits in the guides on How Semaglutide Works and Tirzepatide Safety Basics, and program-by-program differences are compared in Choosing A GLP-1 Program.

What a month costs, and what moves that number

Generic tablets of this medicine are among the least expensive prescriptions in American pharmacies, which is unusual for a drug this widely used. That single fact reframes the cost question: for most people the meaningful expense is not the molecule, it is what wraps around it.

Telehealth programs are priced as recurring monthly plans, and those plans are tracked here on a cash-pay basis, meaning the plan or membership fee a new self-pay patient can start on. For programs in the directory that include this medication, the lowest recurring self-pay figure tracked is $49 per month and the median is $125 per month. Advertised plan prices change often, so treat those as a snapshot rather than a fixed rate.

Five things move what you pay:

• Generic against brand. A branded extended-release product with no generic equivalent sits in a different cost world from a generic immediate-release tablet.
• Fill size. A ninety day supply and a thirty day supply are not the same cost per month at most pharmacies.
• What the plan fee includes. Some monthly plan fees cover clinician visits, messaging and shipping but not the drug itself. Others bundle the medication. That distinction changes the real total more than any headline figure.
• Lab work. Kidney function and A1c testing may be included, billed separately, or left for you to arrange.
• Payment route. Paying cash at a pharmacy and paying a telehealth plan fee are separate tracks, and mixing them together produces a number that describes nobody’s actual bill.

On the insurance side, generic versions are commonly placed on low cost-sharing tiers, but formularies, deductibles and pharmacy networks differ by plan and state. Independent research on how prescription cost sharing varies across US health plans explains why two people with the same prescription pay different amounts. Verify your own coverage with your plan before you assume anything.

If you are comparing a monthly plan against a straightforward pharmacy fill, annualise both before deciding.

A worked example of how the cost comparison is laid out appears in the Free Savings Report.

How telehealth programs handle prescribing

Not every telehealth service that mentions metabolic health will actually treat type 2 diabetes. Some are weight-focused and will refer you elsewhere for glucose management. That is the first thing to check, and the difference is often buried in the intake form.

After that, the variables that matter are consistent across programs listed in the Telehealth Provider Directory:

• Whether a licensed clinician reviews recent labs, including kidney function, before writing a prescription.
• Whether the program orders those labs, accepts results from your own doctor, or expects you to arrange them.
• How often you see or message a clinician after the first prescription, and who handles refills.
• Which states the service covers, since telemedicine prescribing rules and clinician licensure are set state by state.
• Whether the pharmacy is disclosed, and whether shipping is included.
• Whether the service can bill insurance or operates cash pay only.

Those dimensions are also what the ratings on this site weigh, and the weighting is set out on the Scoring Methodology page. Ongoing analysis of how programs handle chronic condition prescribing is collected in the Latest Telehealth Analysis.

Questions worth asking before the first refill

• What is my current eGFR, and how often will kidney function be rechecked?
• Should I start on immediate release or extended release, and why that choice for me?
• Which of my other medicines and supplements interact with this one?
• What should I do about doses before imaging with contrast dye or before surgery?
• How much alcohol, if any, is reasonable while taking this?
• Will B12 be checked, and how often?
• What symptoms mean I should stop and call, and what number do I call after hours?
• If digestive side effects do not settle in a few weeks, what